{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:07:35Z","timestamp":1785413255321,"version":"3.56.0"},"reference-count":17,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"unspecified","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,7,7]]},"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate 6-month clinical outcomes in obese patients with psoriatic arthritis (PsA) who initiated tirzepatide concurrently with biologic therapy compared with those starting biologics alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Propensity score-matched comparative study at tertiary care rheumatology centres. Patients with PsA with body mass index (BMI) \u226530\u2009kg\/m\u00b2 or \u226527\u2009kg\/m\u00b2 with at least one weight-related comorbidity initiating tirzepatide (2.5 mg\/week, uptitrated to 5 mg\/week after 1 month) with biologic therapy were prospectively enrolled from January 2025. Controls initiating biologics alone (2021\u20132025) were matched 1:2 on BMI, disease duration, Disease Activity Index for Psoriatic Arthritis (DAPSA) and Psoriasis Area and Severity Index (PASI). Outcomes at 6 months included minimal disease activity, DAPSA low disease activity (\u226414), PsA Impact of Disease-12 (PsAID-12) Patient Acceptable Symptom State (PASS \u22644), Health Assessment Questionnaire (HAQ \u22640.5), PASI \u22641, Visual Analogue Scale pain and C reactive protein (CRP). Continuous outcomes were additionally analysed with ANCOVA adjusted for baseline and a mixed (time \u00d7 group) model.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-one patients completed 6 months and were matched to 62 controls. Baseline characteristics were well balanced. The tirzepatide group showed greater BMI reduction (\u22122.9\u00b12.0\u2009vs +0.4\u00b11.2\u2009kg\/m\u00b2, p&lt;0.001) and lower CRP (4.2\u00b13.8\u2009vs 7.7\u00b13.0\u2009mg\/L, p&lt;0.001). PsAID-12 PASS was achieved by 48% vs 21% (OR 3.44, 95% CI 1.38 to 8.63, p=0.009), HAQ\u22640.5 by 42% vs 18% (OR 3.27, 95% CI 1.26 to 8.44, p=0.022) and PASI\u22641 by 74% vs 52% (OR 2.59, 95% CI 1.03 to 6.56, p=0.045). Baseline-adjusted ANCOVA confirmed significant 6-month differences in favour of tirzepatide for BMI, CRP, PsAID-12 and DAPSA, with a significant time \u00d7 group interaction for BMI, CRP and PsAID-12.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Concurrent tirzepatide and biologic initiation in obese PsA was associated with significantly better patient-reported outcomes, skin disease control, baseline-adjusted joint disease activity and CRP reduction at 6 months.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2026-006830","type":"journal-article","created":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:35:15Z","timestamp":1785411315000},"page":"e006830","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Concurrent initiation of tirzepatide and biologics improves patient-reported outcomes in obese psoriatic arthritis: a propensity score-matched study"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct06588296","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2573-5930","authenticated-orcid":false,"given":"Vincenzo","family":"Venerito","sequence":"first","affiliation":[{"name":"Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lopalco","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiana","family":"Colaprico","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Catamer\u00f2","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7479-4462","authenticated-orcid":false,"given":"Fabio","family":"Cacciapaglia","sequence":"additional","affiliation":[{"name":"Libera Universit\u00e0 Mediterranea Jean Monnet, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0474-5344","authenticated-orcid":false,"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[{"name":"Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari Aldo Moro, Bari, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,7,30]]},"reference":[{"key":"2026073004350593000_12.3.e006830.1","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1194-8","article-title":"Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis","volume":"18","author":"Lupoli","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2026073004350593000_12.3.e006830.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204448"},{"key":"2026073004350593000_12.3.e006830.3","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/acr.21711","article-title":"Obesity and the prediction of minimal disease activity: a prospective study in psoriatic arthritis","volume":"65","author":"di Minno","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026073004350593000_12.3.e006830.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2016.01.010"},{"key":"2026073004350593000_12.3.e006830.5","doi-asserted-by":"crossref","unstructured":"The Lancet Rheumatology . GLP-1 receptor agonists in rheumatic disease. Lancet Rheumatol 2026;8. doi:10.1016\/S2665-9913(26)00011-1","DOI":"10.1016\/S2665-9913(26)00011-1"},{"key":"2026073004350593000_12.3.e006830.6","doi-asserted-by":"crossref","first-page":"103864","DOI":"10.1016\/j.autrev.2025.103864","article-title":"Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions","volume":"24","author":"Bilgin","year":"2025","journal-title":"Autoimmun Rev"},{"key":"2026073004350593000_12.3.e006830.7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2206038"},{"key":"2026073004350593000_12.3.e006830.8","unstructured":"Merola JF , Engel B , Engbers S , et al . Ixekizumab concomitantly administered with tirzepatide in adults with psoriatic arthritis and obesity or overweight: the TOGETHER-PsA phase 3b trial. Ann Rheum Dis 2026. doi:10.1136\/ard-2025-227434"},{"key":"2026073004350593000_12.3.e006830.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.21972"},{"key":"2026073004350593000_12.3.e006830.10","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.102053"},{"key":"2026073004350593000_12.3.e006830.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205207"},{"key":"2026073004350593000_12.3.e006830.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-019-1810-5","article-title":"Weight loss improves disease activity in patients with psoriatic arthritis and obesity: an interventional study","volume":"21","author":"Klingberg","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2026073004350593000_12.3.e006830.13","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1093\/rheumatology\/keae006","article-title":"Effectiveness of sequential lines of biologic and targeted small-molecule drugs in psoriatic arthritis: a systematic review","volume":"63","author":"Gollins","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026073004350593000_12.3.e006830.14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.5152\/ArchRheumatol.2025.25030","article-title":"Effect of nutritional ingredients on disease activation in psoriatic arthritis","volume":"40","author":"Varkal","year":"2025","journal-title":"Arch Rheumatol"},{"key":"2026073004350593000_12.3.e006830.15","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/rheumatology\/kead261","article-title":"Socioeconomic deprivation is associated with reduced response and lower treatment persistence with TNF inhibitors in rheumatoid arthritis","volume":"63","author":"Zhao","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"2026073004350593000_12.3.e006830.16","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew274"},{"key":"2026073004350593000_12.3.e006830.17","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.100497"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2026-006830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:35:25Z","timestamp":1785411325000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2026-006830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,7,30]]},"published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1136\/rmdopen-2026-006830"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2026-006830","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}